Estrogen receptor mutations found in breast cancer metastases integrated with the molecular pharmacology of selective ER modulators

Journal of the National Cancer Institute

Volumn 107, Issue 6, 2015, Pages

  Jordan, V Craig ^a   Curpan, Ramona ^b   Maximov, Philipp Y ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ACADEMY OF ROMANIAN SCIENTISTS   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ESTROGEN; ESTROGEN RECEPTOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; ASPARTIC ACID; TYROSINE;

ARTICLE; BREAST METASTASIS; CIRCULATING TUMOR CELL; ESTROGEN ACTIVITY; GENE ACTIVATION; GENE MUTATION; HUMAN; LIGAND BINDING; MOLECULAR MODEL; NONHUMAN; PRIORITY JOURNAL; RNA TRANSLATION; SIGNAL TRANSDUCTION; BREAST TUMOR; FEMALE; GENETICS; MUTATION; PATHOLOGY; XENOGRAFT;

ASPARTIC ACID; BREAST NEOPLASMS; FEMALE; HETEROGRAFTS; HUMANS; MUTATION; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TYROSINE;

EID: 84930702846     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djv075     Document Type: Article

References (118)

1. Li S, Shen D, Shao J, et al. Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived Xenografts. Cell Rep. 2013;4(6):1116-1130.
2. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, et al. D538G Mutation in Estrogen Receptor-alpha: A Novel Mechanism for Acquired Endocrine Resistance in Breast Cancer. Cancer Res. 2013;73(23):6856-6864.
3. Toy W, Shen Y, Won H, et al. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat Genet. 2013;45(12):1439-1445.
4. Robinson DR, Wu YM, Vats P, et al. Activating ESR1 mutations in hormoneresistant metastatic breast cancer. Nat Genet. 2013;45(12):1446-1451.
5. Yu M, Bardia A, Aceto N, et al. Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. Science. 2014;345(6193):216-220.
6. Jeselsohn R, Yelensky R, Buchwalter G, et al. Emergence of constitutively active estrogen receptor-alpha mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res. 2014;20(7):1757-1767.
7. Davies C, Godwin J, Gray R, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771-784.
8. Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013;381(9869):805-816.
9. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010;28(3):509-518.
10. Jensen EV, Jordan VC. The estrogen receptor: A model for molecular medicine. Clin Cancer Res. 2003;9(6):1980-1989.
11. Jordan VC, Brodie AM. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids. 2007;72(1):7-25.
12. Lieberman ME, Gorski J, Jordan VC. An estrogen receptor model to describe the regulation of prolactin synthesis by antiestrogens in vitro. J Biol Chem. 1983;258(8):4741-4745.
13. Jordan VC, Lieberman ME. Estrogen-stimulated prolactin synthesis in vitro. Classification of agonist, partial agonist, and antagonist actions based on structure. Mol Pharmacol. 1984;26(2):279-285.
14. Jordan VC, Koch R, Mittal S, et al. Oestrogenic and antioestrogenic actions in a series of triphenylbut-1-enes: modulation of prolactin synthesis in vitro. Br J Pharmacol. 1986;87(1):217-223.
15. Jordan VC. Biochemical pharmacology of antiestrogen action. Pharmacol Rev. 1984;36(4):245-276.
16. Jordan VC. Laboratory models of breast cancer to aid the elucidation of antiestrogen action. J Lab Clin Med. 1987;109(3):267-277.
17. Greene GL, Gilna P, Waterfield M, et al. Sequence and expression of human estrogen receptor complementary DNA. Science. 1986;231(4742):1150-1154.
18. Green S, Chambon P. A superfamily of potentially oncogenic hormone receptors. Nature. 1986;324(6098):615-617.
19. Brzozowski AM, Pike ACW, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997;389(6652):753-758.
20. Montano MM, Muller V, Trobaugh A, et al. The carboxy-terminal F domain of the human estrogen receptor: role in the transcriptional activity of the receptor and the effectiveness of antiestrogens as estrogen antagonists. Mol Endocrinol. 1995;9(7):814-825.
21. Schwartz JA, Zhong L, Deighton-Collins S, et al. Mutations targeted to a predicted helix in the extreme carboxyl-terminal region of the human estrogen receptor-alpha alter its response to estradiol and 4-hydroxytamoxifen. J Biol Chem. 2002;277(15):13202-13209.
22. Yang J, Singleton DW, Shaughnessy EA, et al. The F-domain of estrogen receptor-alpha inhibits ligand induced receptor dimerization. Mol Cell Endocrinol. 2008;295(1-2):94-100.
23. Koide A, Zhao C, Naganuma M, et al. Identification of regions within the F domain of the human estrogen receptor alpha that are important for modulating transactivation and protein-protein interactions. Mol Endocrinol. 2007;21(4):829-842.
24. Kumar V, Green S, Stack G, et al. Functional domains of the human estrogen receptor. Cell. 1987;51(6):941-951.
25. Ponglikitmongkol M, White JH, Chambon P. Synergistic activation of transcription by the human estrogen receptor bound to tandem responsive elements. EMBO J. 1990;9(7):2221-2231.
26. Tora L, Mullick A, Metzger D, et al. The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J. 1989;8(7):1981-1986.
27. Jiang SY, Jordan VC. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor. J Natl Cancer Inst. 1992;84(8):580-591.
28. Levenson AS, Jordan VC. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor. Cancer Res. 1998;58(9):1872-1875.
29. Masamura S, Santner SJ, Heitjan DF, et al. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab. 1995;80(10):2918-2925.
30. Sweeney EE, McDaniel RE, Maximov PY, et al. Models and Mechanisms of Acquired Antihormone Resistance in Breast Cancer: Significant Clinical Progress Despite Limitations. Horm Mol Biol Clin Investig. 2012;9(2):143-163.
31. Pink JJ, Jordan VC. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines. Cancer Res. 1996;56(10):2321-2330.
32. Welshons WV, Jordan VC. Adaptation of estrogen-dependent MCF-7 cells to low estrogen (phenol red-free) culture. Eur J Cancer Clin Oncol. 1987;23(12):1935-1939.
33. Moelans CB, Holst F, Hellwinkel O, et al. ESR1 amplification in breast cancer by optimized RNase FISH: frequent but low-level and heterogeneous. PLoS One. 2013;8(12):e84189.
34. Murphy CS, Pink JJ, Jordan VC. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions. Cancer Res. 1990;50(22):7285-7292.
35. Pink JJ, Bilimoria MM, Assikis J, et al. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation. Br J Cancer. 1996;74(8):1227-1236.
36. Sluyser M, Mester J. Oncogenes homologous to steroid receptors? Nature. 1985;315(6020):546.
37. Sluyser M. Steroid/thyroid receptor-like proteins with oncogenic potential: A review. Cancer Res. 1990;50(3):451-458.
38. Scott GK, Kushner P, Vigne JL, et al. Truncated forms of DNA-binding estrogen receptors in human breast cancer. J Clin Invest. 1991;88(2):700-706.
39. Karnik PS, Kulkarni S, Liu XP, et al. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 1994;54(2):349-353.
40. Fuqua SA, Fitzgerald SD, Chamness GC, et al. Variant human breast tumor estrogen receptor with constitutive transcriptional activity. Cancer Res. 1991;51(1):105-109.
41. Fuqua SA, Fitzgerald SD, Allred DC, et al. Inhibition of estrogen receptor action by a naturally occurring variant in human breast tumors. Cancer Res. 1992;52(2):483-486.
42. Zhang QX, Borg A, Wolf DM, et al. An estrogen receptor mutant with strong hormone-independent activity from a metastatic breast cancer. Cancer Res. 1997;57(7):1244-1249.
43. Arnold SF, Obourn JD, Jaffe H, et al. Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol. 1995;9(1):24-33.
44. Sun J, Zhou W, Kaliappan K, et al. ERalpha phosphorylation at Y537 by Src triggers E6-AP-ERalpha binding, ERalpha ubiquitylation, promoter occupancy, and target gene expression. Mol Endocrinol. 2012;26(9):1567-1577.
45. Castoria G, Giovannelli P, Lombardi M, et al. Tyrosine phosphorylation of estradiol receptor by Src regulates its hormone-dependent nuclear export and cell cycle progression in breast cancer cells. Oncogene. 2012;31(46):4868-4877.
46. Fan P, Agboke FA, McDaniel RE, et al. Inhibition of c-Src blocks oestrogeninduced apoptosis and restores oestrogen-stimulated growth in long-term oestrogen-deprived breast cancer cells. Eur J Cancer. 2014;50(2):457-468.
47. Suresh PS, Ma S, Migliaccio A, et al. Protein-tyrosine phosphatase h1 increases breast cancer sensitivity to antiestrogens by dephosphorylating estrogen receptor at tyr537. Mol Cancer Ther. 2014;13(1):230-238.
48. Pearce ST, Liu H, Jordan VC. Modulation of estrogen receptor alpha function and stability by tamoxifen and a critical amino acid (Asp-538) in helix 12. J Biol Chem. 2003;278(9):7630-7638.
49. Shiau AK, Barstad D, Loria P, et al. The Structural Basis of Estrogen Receptor/Coactivator Recognition and the Antagonism of This Interaction by Tamoxifen. Cell. 1998;95(7):927-937.
50. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295(23):2727-2741.
51. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila). 2010;3(6):696-706.
52. Osborne CK, Coronado EB, Robinson JP. Human breast cancer in the athymic nude mouse: cytostatic effects of long-term antiestrogen therapy. Eur J Cancer Clin Oncol. 1987;23(8):1189-1196.
53. Gottardis MM, Jordan VC. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 1988;48(18):5183-5187.
54. Gottardis MM, Wagner RJ, Borden EC, et al. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro. Cancer Res. 1989;49(17):4765-4769.
55. Canney PA, Griffiths T, Latief TN, et al. Clinical significance of tamoxifen withdrawal response. Lancet. 1987;1(8523):36.
56. Howell A, Dodwell DJ, Anderson H, et al. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer. Ann Oncol. 1992;3(8):611-617.
57. Gottardis MM, Jiang SY, Jeng MH, et al. Inhibition of tamoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 1989;49(15):4090-4093.
58. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20(16):3386-3395.
59. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20(16):3396-3403.
60. Mullick A, Chambon P. Characterization of the estrogen receptor in two antiestrogen-resistant cell lines, LY2 and T47D. Cancer Res. 1990;50(2):333-338.
61. Wolf DM, Jordan VC. Characterization of tamoxifen stimulated MCF-7 tumor variants grown in athymic mice. Breast Cancer Res Treat. 1994;31(1):117-127.
62. Wolf DM, Jordan VC. The estrogen receptor from a tamoxifen stimulated MCF-7 tumor variant contains a point mutation in the ligand binding domain. Breast Cancer Res Treat. 1994;31(1):129-138.
63. Jeng MH, Jiang SY, Jordan VC. Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER. Cancer Lett. 1994;82(2):123-128.
64. Catherino WH, Wolf DM, Jordan VC. A naturally occurring estrogen receptor mutation results in increased estrogenicity of a tamoxifen analog. Mol Endocrinol. 1995;9(8):1053-1063.
65. Levenson AS, Catherino WH, Jordan VC. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J Steroid Biochem Mol Biol. 1997;60(5-6):261-268.
66. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362(8):686-696.
67. Vajdos FF, Hoth LR, Geoghegan KF, et al. The 2.0 A crystal structure of the ERalpha ligand-binding domain complexed with lasofoxifene. Protein Sci. 2007;16(5):897-905.
68. Liu H, Lee ES, Deb Los Reyes A, et al. Silencing and reactivation of the selective estrogen receptor modulator-estrogen receptor alpha complex. Cancer Res. 2001;61(9):3632-3639.
69. MacGregor Schafer J, Liu H, Bentrem DJ, et al. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351. Cancer Res. 2000;60(18):5097-5105.
70. Liu H, Park WC, Bentrem DJ, et al. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells. J Biol Chem. 2002;277(11):9189-9198.
71. Jordan VC, Schafer JM, Levenson AS, et al. Molecular classification of estrogens. Cancer Res. 2001;61(18):6619-6623.
72. Obiorah I, Sengupta S, Curpan R, et al. Defining the conformation of the estrogen receptor complex that controls estrogen-induced apoptosis in breast cancer. Mol Pharmacol. 2014;85(5):789-799.
73. Obiorah IE, Jordan VC. Differences in the rate of oestrogen-induced apoptosis in breast cancer by oestradiol and the triphenylethylene bisphenol. Br J Pharmacol. 2014;171(17):4062-4072.
74. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476-486.
75. Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: A phase 2 randomized study. JAMA. 2009;302(7):774-780.
76. Obiorah I, Jordan VC. 2012 NAMS/PFIZER-Wulf H. Utian endowed lecture. The scientific rationale for a delay after menopause in the use of conjugated equine estrogens in postmenopausal women that causes a reduction in breast cancer incidence and mortality. Menopause. 2013;20(4):372-382.
77. Yao K, Lee ES, Bentrem DJ, et al. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice. Clin Cancer Res. 2000;6(5):2028-2036.
78. Haddow A, Watkinson JM, Paterson E, et al. Influence of Synthetic Oestrogens on Advanced Malignant Disease. Br Med J. 1944;2(4368):393-398.
79. Wrenn CK, Katzenellenbogen BS. Structure-function analysis of the hormone binding domain of the human estrogen receptor by regionspecific mutagenesis and phenotypic screening in yeast. J Biol Chem. 1993;268(32):24089-24098.
80. Zhuang Y, Katzenellenbogen BS, Shapiro DJ. Estrogen receptor mutants which do not bind 17 beta-estradiol dimerize and bind to the estrogen response element in vivo. Mol Endocrinol. 1995;9(4):457-466.
81. Mahfoudi A, Roulet E, Dauvois S, et al. Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists. Proc Natl Acad Sci U S A. 1995;92(10):4206-4210.
82. Montano MM, Ekena K, Krueger KD, et al. Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estro gens and estrogens as antiestrogens and discriminate among different antiestrogens. Mol Endocrinol. 1996;10(3):230-242.
83. Lazennec G, Ediger TR, Petz LN, et al. Mechanistic aspects of estrogen receptor activation probed with constitutively active estrogen receptors: correlations with DNA and coregulator interactions and receptor conformational changes. Mol Endocrinol. 1997;11(9):1375-1386.
84. Pakdel F, Reese JC, Katzenellenbogen BS. Identification of charged residues in an N-terminal portion of the hormone-binding domain of the human estrogen receptor important in transcriptional activity of the receptor. Mol Endocrinol. 1993;7(11):1408-1417.
85. Weis KE, Ekena K, Thomas JA, et al. Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein. Mol Endocrinol. 1996;10(11):1388-1398.
86. Zhao C, Koide A, Abrams J, et al. Mutation of Leu-536 in human estrogen receptor-alpha alters the coupling between ligand binding, transcription activation, and receptor conformation. J Biol Chem. 2003;278(29):27278-27286.
87. De Mattos-Arruda L, Weigelt B, Cortes J, et al. Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cellfree tumor DNA: A proof-of-principle. Ann Oncol. 2014;25(9):1729-1735.
88. Skafar DF, Koide S. Understanding the human estrogen receptor-alpha using targeted mutagenesis. Mol Cell Endocrinol. 2006;246(1-2):83-90.
89. Sanchez CG, Ma CX, Crowder RJ, et al. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res. 2011;13(2):R21.
90. Levenson AS, Jordan VC. MCF-7: The first hormone-responsive breast cancer cell line. Cancer Res. 1997;57(15):3071-3078.
91. Fuqua SA, Wiltschke C, Zhang QX, et al. A hypersensitive estrogen receptor-alpha mutation in premalignant breast lesions. Cancer Res. 2000;60(15):4026-4029.
92. Jordan VC. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J Natl Cancer Inst. 1998;90(13):967-971.
93. Gee AC, Carlson KE, Martini PG, et al. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol Endocrinol. 1999;13(11):1912-1923.
94. DuSell CD, Umetani M, Shaul PW, et al. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol. 2008;22(1):65-77.
95. Nelson ER, Wardell SE, Jasper JS, et al. 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. Science. 2013;342(6162):1094-1098.
96. Wu Q, Ishikawa T, Sirianni R, et al. 27-Hydroxycholesterol promotes cellautonomous, ER-positive breast cancer growth. Cell Rep. 2013;5(3):637-645.
97. Kitahara CM, Berrington de Gonzalez A, Freedman ND, et al. Total cholesterol and cancer risk in a large prospective study in Korea. J Clin Oncol. 2011;29(12):1592-1598.
98. Jordan VC. Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell. 2004;5(3):207-213.
99. Di Leo A, Jerusalem G, Petruzelka L, et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014;106(1). doi:10.1093/jnci/djt337.
100. Jordan VC. The 38th David A. Karnofsky lecture: The paradoxical actions of estrogen in breast cancer-survival or death? J Clin Oncol. 2008;26(18):3073-3082.
101. Jordan VC. Linking estrogen-induced apoptosis with decreases in mortality following long-term adjuvant tamoxifen therapy. J Natl Cancer Inst. 2014;106(11). doi:10.1093/jnci/dju296.
102. Wolf DM, Jordan VC. A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res. 1993;127:23-33.
103. Song RX, Mor G, Naftolin F, et al. Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J Natl Cancer Inst. 2001;93(22):1714-1723.
104. Jordan VC. The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer. Endocr Relat Cancer. 2014;22(1):R1-R31.
105. Lewis JS, Meeke K, Osipo C, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst. 2005;97(23):1746-1759.
106. Giuliano M, Schiff R, Osborne CK, et al. Biological mechanisms and clinical implications of endocrine resistance in breast cancer. Breast. 2011;20(Suppl 3):S42-S49.
107. Arpino G, Weiss H, Lee AV, et al. Estrogen receptor-positive, progesterone receptor-negative breast cancer: Association with growth factor receptor expression and tamoxifen resistance. J Natl Cancer Inst. 2005;97(17):1254-1261.
108. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96(12):926-935.
109. Jordan VC. Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem. 2003;46(6):883-908.
110. Fan P, Agboke FA, Cunliffe HE, et al. A molecular model for the mechanism of acquired tamoxifen resistance in breast cancer. Eur J Cancer. 2014;50(16):2866-2876.
111. Fan P, Cunliffe HE, Griffith OL, et al. Identification of gene regulation patterns underlying both oestrogen-and tamoxifen-stimulated cell growth through global gene expression profiling in breast cancer cells. Eur J Cancer. 2014;50(16):2877-2886.
112. Wardell SE, Nelson ER, Chao CA, et al. Bazedoxifene exhibits antiestrogenic activity in animal models of tamoxifen-resistant breast cancer: implications for treatment of advanced disease. Clin Cancer Res. 2013;19(9):2420-2431.
113. Babayan A, Hannemann J, Spotter J, et al. Heterogeneity of estrogen receptor expression in circulating tumor cells from metastatic breast cancer patients. PLoS One. 2013;8(9):e75038.
114. Lewis-Wambi JS, Kim H, Curpan R, et al. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol. 2011;80(4):610-620.
115. Wittmann BM, Sherk A, McDonnell DP. Definition of functionally important mechanistic differences among selective estrogen receptor downregulators. Cancer Res. 2007;67(19):9549-9560.
116. Ingle JN, Ahmann DL, Green SJ, et al. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981;304(1):16-21.
117. Jordan VC. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer. 2014;21(3):R235-R246.
118. Tzukerman MT, Esty A, Santiso-Mere D, et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol. 1994;8(1):21-30.